Expanding on this, a separate study using a nationwide multicenter database of electronic health records of over 1.6 million patients with T2D with no prior diagnoses of OACs and who were prescribed GLP‐1 RAs, insulins, or metformin, found no clear association between GLP‐1 RA use and a reduced risk of developing postmenopausal breast cancer [91]. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.